Drug Trial Radar · NCT06484855
Safety and Tolerability of IBI355 in Patients With Primary Sjogren's Syndrome
Last checked: Nov 19, 2026Latest source record: Sep 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
30
Actual
Start
Jul 14, 2024
Primary completion
Jun 21, 2025
Study completion Jul 25, 2025
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of multiple ascending doses of IBI355 in primary Sjogren's syndrome (pSS) patients. This study also aims to evaluate the anti-Drug antibody after multiple ascending doses of IBI355 in pSS patients.
Conditions
- Primary Sjögren's Syndrome
Interventions
IBI355Drug
IBI355 IV. Q4W
IBI355 placeboDrug
IBI355 placebo IV. Q4W
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of adverse events and serious adverse eventsTime frame: up to week 24
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.